GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT00886626

CompletedPhase 2Results posted

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children: A Randomized, Controlled, Pilot Study

Lead sponsor

University of Minnesota

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•BMI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00886626

Org study ID0902M59181

Timeline

Milestones

Study first posted2009-04-23estimated

Results first posted2012-08-17estimated

Last update posted2012-10-29estimated

Study start2009-05 (month precision)

Primary completion2011-02actual (month precision)

Study completion2011-02actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age8 Years

Maximum age19 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Age 8-19 years old

•Subject able to give assent, and parent/guardian capable of giving consent on behalf of the child

•Body mass index (BMI) ≥ 99th percentile (based on gender and age)

Exclusion criteria

•Type 1 or 2 diabetes mellitus

•Initiation of a new drug therapy within the past 30 days prior to the screening visit

•BMI ≥ 55

•History of weight loss surgery

•Obesity from a genetic cause (e.g., Prader-Willi)

•Central nervous system injury or severe neurological impairment

•Known systolic or diastolic dysfunction or heart failure

•Females who are currently pregnant or planning to become pregnant

•Liver enzymes > 2.5 times upper limit of normal

•Severe renal impairment (defined as creatinine clearance <30 mL/min)

•Gastrointestinal disease

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint

Primary/protocol endpoint

Change in Body Mass Index (BMI)

Time frame:3-month

BMI, change

change from baseline, improvement

Posted result

Group	Value (mean), change in kg/m^2	95% CI
Exenatide	-0.9	—
Control	0.84	—

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.
Obesity (Silver Spring, Md.)2012 Feb (month)PMID22076596doi:10.1038/oby.2011.337via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.